VEEV

Veeva Systems Inc Class A
NYSEHEALTHCAREHEALTH INFORMATION SERVICES

Key Statistics

Market Cap
$32.68B
P/E Ratio
34.51
EPS
$5.83
Beta
0.94
52W High
$310.50
52W Low
$148.05
50-Day MA
$175.52
200-Day MA
$205.16
Dividend Yield
Profit Margin
28.40%
Forward P/E
21.60
PEG Ratio
0.88

About Veeva Systems Inc Class A

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.

Official WebsiteUSAFY End: January

Fundamentals

Revenue (TTM)$3.32B
Gross Profit (TTM)$2.49B
EBITDA$1.03B
Operating Margin30.90%
Return on Equity13.90%
Return on Assets7.30%
Revenue/Share (TTM)$20.26
Book Value$44.83
Price-to-Book4.33
Price-to-Sales (TTM)9.85
EV/Revenue7.34
EV/EBITDA24.49
Quarterly Earnings Growth (YoY)14.60%
Quarterly Revenue Growth (YoY)16.30%
Shares Outstanding$162.44M
Float$148.91M
% Insiders8.58%
% Institutions89.69%

Historical Volatility

HV 10-Day
47.10%
HV 20-Day
41.23%
HV 30-Day
46.39%
HV 60-Day
49.20%
HV Rank
84.1%

Volatility is currently expanding

Analyst Ratings

Consensus ($244.14 target)
8
Strong Buy
13
Buy
7
Hold
1
Sell

Latest News

Veeva Systems: Steady Execution, Attractive P/E Multiples

Veeva Systems stands out as a compelling buy amid a potential market rotation into lagging software stocks. VEEV benefits from a highly regulated customer base, strong growth and margin profile, and robust sales execution. After a near-20% YTD decline and recent post-earnings volatility, VEEV's valuation is now especially attractive.

Seeking Alpha7/24/2026Positive
Wall Street Analysts Think Veeva (VEEV) Is a Good Investment: Is It?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research7/23/2026Neutral
Veeva (VEEV) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research7/7/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VEEV and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026